Table 2.

Characteristics and Treatment of Patients who had VTE

Age, y	Gender	DVT/PE	Symptom	Medication, period	contrast-enhanced CT	Post D-dimer, μg/ml
39	Male	DVT	asymptomatic	Apixaban, 6 M	Not performed	4.5
47	Female	DVT	asymptomatic	Warfarin, 3 M	Disappear	3.7
24	Male	DVT	asymptomatic	Warfarin, 3 M	Not performed	1.7
39	Male	PE	asymptomatic	Warfarin, 3 M	Disappear	4.8
43	Male	PE	asymptomatic	Warfarin, 1 M	Disappear	4.2
27	Male	PE	asymptomatic	Warfarin, 1 M	Disappear	2.9
31	Male	PE and DVT	asymptomatic	Edoxaban Tosilate Hydrate, 3 M	Disappear	4.4
24	Male	PE	asymptomatic	Apixaban, 3 M	Disappear	4.2
37	Male	PE and DVT	asymptomatic	Edoxaban Tosilate Hydrate, 3 M	Not performed	3.7
50	Female	PE	asymptomatic	Apixaban, 3 M	Not performed	2.8
23	Female	DVT	Homan’s sign+	Rivaroxaban、3 M	Disappear	3.7
47	Female	DVT	asymptomatic	Apixaban, 3 M	Disappear	3.3
23	Female	PE and DVT	asymptomatic	Apixaban, 3 M	Not performed	3
39	Male	DVT	asymptomatic	Apixaban, 3 M	Disappear	1.8
43	Male	DVT	asymptomatic	Apixaban, 3 M	Not performed	2.5

VTE Venous thromboembolism, DVT Deep vein thrombosis, PE Pulmonary embolism